OTCMKTS:UCBJF UCB (UCBJF) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free UCBJF Stock Alerts $132.00 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share Today's Range$132.00▼$132.0050-Day Range$116.60▼$133.6852-Week Range$69.70▼$133.68VolumeN/AAverage Volume70 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest Get UCB alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About UCB Stock (OTCMKTS:UCBJF)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More UCBJF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UCBJF Stock News HeadlinesMay 11, 2024 | americanbankingnews.comUCB (OTCMKTS:UCBJF) Stock Price Passes Above Fifty Day Moving Average of $124.07April 25, 2024 | msn.comUCB SA goes ex dividend tomorrowApril 24, 2024 | seekingalpha.comArtisan Global Equity Fund Q1 2024 CommentaryApril 24, 2024 | seekingalpha.comArtisan International Fund Q1 2024 CommentaryMarch 22, 2024 | finance.yahoo.comUCB Convening Notice to the General Meeting of the Shareholders 2024March 7, 2024 | realmoney.thestreet.comUCB price target raised by EUR 13 at BarclaysFebruary 28, 2024 | msn.comUCB SA reports FY resultsFebruary 10, 2024 | marketwatch.comStocks A-ZFebruary 4, 2024 | msn.comInvestors growing more bullish on SMID cap biotech stocksNovember 14, 2023 | msn.comUCB launches newly approved psoriasis drug Bimzelx in USNovember 11, 2023 | finance.yahoo.comPost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)November 10, 2023 | finance.yahoo.comUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023October 18, 2023 | finance.yahoo.comBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | finance.yahoo.comUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravisOctober 13, 2023 | finance.yahoo.comUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023October 12, 2023 | finance.yahoo.comPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaJune 27, 2023 | finance.yahoo.comFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in AdultsFebruary 22, 2023 | finance.yahoo.comChina Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.October 20, 2022 | finance.yahoo.comUCB SA (UCBJF)April 25, 2022 | finance.yahoo.comHere's Why Momentum in UCB SA (UCBJF) Should Keep goingMarch 31, 2022 | msn.comWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"March 25, 2022 | finanznachrichten.deUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022February 7, 2022 | seekingalpha.comBiogen signs licensing deal with Xbrane for potential biosimilar to CimziaJanuary 23, 2022 | finance.yahoo.comZGNX Jan 2022 7.000 callJanuary 21, 2022 | msn.comWhy Zogenix Flew Higher Before Leveling Off This WeekSee More Headlines Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/21/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:UCBJF CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees8,703Year Founded1928Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5.27 billion Price / SalesN/A Cash Flow$7.90 per share Price / Cash Flow16.70 Book Value$50.52 per share Price / Book2.61Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.53 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jean-Christophe Tellier (Age 65)CEO & Executive Director Comp: $4.37MMs. Sandrine Dufour CFA (Age 58)Executive VP, CFO & Chief Corporate Development Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)Executive Vice President of Supply & Technology Solutions Dr. Dhavalkumar D. Patel M.D. (Age 63)Ph.D., Executive VP & Chief Scientific Officer Ms. Denelle J. Waynick Johnson J.D. (Age 57)Executive VP & General Counsel Mr. Jean-Luc Fleurial (Age 59)Executive VP & Chief Human Resources Officer Prof. Iris Low-Friedrich (Age 64)Executive VP & Chief Medical Officer Mr. Emmanuel Caeymaex (Age 55)Executive VP of Immunology Solutions & Head of US Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsAntje WitteHead of Investor RelationsMore ExecutivesKey CompetitorsMerck KGaAOTCMKTS:MKGAFGenmab A/SNASDAQ:GMABTeva Pharmaceutical IndustriesNYSE:TEVAAlnylam PharmaceuticalsNASDAQ:ALNYAstellas PharmaOTCMKTS:ALPMYView All Competitors UCBJF Stock Analysis - Frequently Asked Questions Should I buy or sell UCB stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UCBJF shares. View UCBJF analyst ratings or view top-rated stocks. How have UCBJF shares performed in 2024? UCB's stock was trading at $87.10 on January 1st, 2024. Since then, UCBJF shares have increased by 51.5% and is now trading at $132.00. View the best growth stocks for 2024 here. When is UCB's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our UCBJF earnings forecast. How do I buy shares of UCB? Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:UCBJF) was last updated on 5/21/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.